echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Breaking the Cocoon into a Butterfly: Condésai mRNA-edited DC Personalized Tumor Vaccine IND Officially Accepted

    Breaking the Cocoon into a Butterfly: Condésai mRNA-edited DC Personalized Tumor Vaccine IND Officially Accepted

    • Last Update: 2022-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    August 12, 2022/eMedClub News/--On August 9, 2022, China National Medical Products Administration Center for Drug Evaluation (NMPA) announced that Sichuan Kangdesai Medical Technology Co.





    Condésai has received multiple rounds of investment from funds such as BGI, Beijing Enterprises Medical, KIP, Skycom Capital and Tsinghua Tus, with a financing scale of over 100 million yuan
    .

    In order to better promote the progress of multiple clinical trials, the company is currently seeking a new round of financing
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.